证券代码：688277 证券简称：天智航 公告编号：2025-036 北京天智航医疗科技股份有限公司 关于公司高级管理人员离任的公告 （一）提前离任的基本情况 | 姓名 | 离任 | 离任时 | | 原定任期 | | 离任 | 是否继续在上 市公司及其控 | 具体职务（如 | 是否存在未 履行完毕的 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 职务 | 间 | | 到期日 | | 原因 | 股子公司任职 | 适用） | 公开承诺 | | 马敏 | 总裁 | 2025 | 年 8 | 2026 | 年 9 | 工作 | 是 | 第六届董事会 | 是 | | | | 月 28 | 日 | 月 日 7 | | 调整 | | 非独立董事 | | （二）离任对公司的影响 根据《中华人民共和国公司法》《北京天智航医疗科技股份有限公司章程》 等有关规定，马敏先生的辞职报告自送达公司董事会之日起生效。其已按公司相 关规定做好交接工作，其辞职不会影响公司的正常运营。截至本公告披露日，马 敏先生直接持有公司股份 23.10 万股。马敏先生 ...

Group 1: Company Performance - XINWANDA reported a revenue of 26.985 billion yuan, a year-on-year increase of 12.82%, and a net profit of 856 million yuan, up 3.88% [1] - GUANGXUN TECHNOLOGY achieved a revenue of 5.243 billion yuan, a year-on-year increase of 68.59%, and a net profit of 372 million yuan, up 78.98% [1] - NORTHEAST SECURITIES posted a revenue of 2.046 billion yuan, a year-on-year increase of 31.66%, and a net profit of 431 million yuan, up 225.90% [1][2] - SHANXI COAL reported a revenue of 18.053 billion yuan, a year-on-year decrease of 16.30%, and a net profit of 1.014 billion yuan, down 48.44% [3] - SHENGTIAN NETWORK achieved a revenue of 633 million yuan, a year-on-year increase of 17.23%, and a net profit of 52.304 million yuan, up 1186.02% [4] - SANLIAN FORGING reported a revenue of 775 million yuan, a year-on-year increase of 6.86%, and a net profit of 71.335 million yuan, up 3.88% [5][6] - JIAMEI PACKAGING posted a revenue of 1.257 billion yuan, a year-on-year decrease of 8.73%, and a net profit of 19.7416 million yuan, down 65.59% [8] - ANZHENG FASHION achieved a revenue of 1.146 billion yuan, a year-on-year increase of 12.38%, and a net profit of 22.0834 million yuan, turning from a loss of 12.1096 million yuan in the previous year [9] - HUAHENG BIO reported a revenue of 1.489 billion yuan, a year-on-year increase of 46.54%, and a net profit of 115 million yuan, down 23.26% [10] - BAIREN MEDICAL achieved a revenue of 248 million yuan, a year-on-year increase of 30.07%, and a net profit of 71.4006 million yuan, up 102.90% [12] - TIANZHIHANG reported a revenue of 125 million yuan, a year-on-year increase of 114.89%, but a net loss of 57.5482 million yuan, worsening by 23.80% [14] - AIBO MEDICAL achieved a revenue of 787 million yuan, a year-on-year increase of 14.72%, and a net profit of 213 million yuan, up 2.53% [15] - ZHONGSHAN SHIPPING reported a revenue of 12.585 billion yuan, a year-on-year decrease of 4.91%, and a net profit of 2.125 billion yuan, down 14.91% [16] - SHANGHAI XINYANG achieved a revenue of 897 million yuan, a year-on-year increase of 35.67%, and a net profit of 133 million yuan, up 126.31% [17] - SHANCOAL INTERNATIONAL reported a revenue of 9.66 billion yuan, a year-on-year decrease of 31.28%, and a net profit of 655 million yuan, down 49.25% [18] - GUIDANCE reported a revenue of 935 million yuan, a year-on-year increase of 71.55%, and a net profit of 143 million yuan, turning from a loss of 48.9539 million yuan in the previous year [19] - YINGFANGWEI reported a revenue of 1.927 billion yuan, a year-on-year increase of 4.48%, but a net loss of 32.2966 million yuan, worsening from a loss of 22.4024 million yuan in the previous year [21] - CHINA COMMUNICATIONS reported a revenue of 14.665 billion yuan, a year-on-year increase of 2.91%, and a net profit of 1.621 billion yuan, up 1.34% [22] - CHINA GENERAL NUCLEAR reported a revenue of 39.167 billion yuan, a year-on-year decrease of 0.53%, and a net profit of 5.951 billion yuan, down 16.30% [23] - CHINA HEAVY TRUCK reported a revenue of 26.162 billion yuan, a year-on-year increase of 7.22%, and a net profit of 669 million yuan, up 8.10% [24] - SHENGGUANG GROUP achieved a revenue of 9.275 billion yuan, a year-on-year increase of 22.78%, and a net profit of 60.8446 million yuan, up 3.06% [25] Group 2: Dividend Proposals - XINWANDA proposed a cash dividend of 0.6 yuan per 10 shares [1] - SHANXI COAL proposed a cash dividend of 0.36 yuan per 10 shares [3] - ZHONGSHAN SHIPPING proposed a cash dividend of 0.7 yuan per 10 shares [16] - CHINA HEAVY TRUCK proposed a cash dividend of 3.15 yuan per 10 shares [24]

Core Insights - Surgical robots are a significant indicator of a country's medical technology development, with China witnessing a collective rise in this sector, previously dominated by international giants [1][2] Group 1: Company Performance - Tianzhihang (688277) reported a revenue of 125 million yuan for the first half of 2025, marking a year-on-year increase of 114.89%, primarily due to the recovery of industry bidding and a 641.83% increase in sales of orthopedic surgical navigation systems [1] - The company performed over 22,000 surgeries with its Tianzhihang series robots during the reporting period, accumulating over 120,000 surgeries by June 30, 2025 [1] Group 2: Market Dynamics - The domestic market for surgical robots is primarily composed of laparoscopic and orthopedic surgical robots, which together account for approximately 74% of the total market, with orthopedic robots alone representing 47% [2] - The Chinese medical robot market is projected to exceed 22.1 billion yuan by 2025 and reach 80 billion yuan by 2030, with surgical robots holding the largest share (62%) [2] Group 3: Competitive Landscape - As of 2024, 27 orthopedic surgical robots have been approved in China, making up 47% of all approved surgical robots, indicating a highly competitive environment [3] - The introduction of orthopedic surgical robots into clinical reimbursement lists across over 20 provinces has significantly boosted market growth [2][3] Group 4: International Expansion - The global orthopedic surgical robot market is expected to grow from approximately 1.7 billion yuan in 2016 to 56.7 billion yuan by 2030, with a compound annual growth rate of about 16.8% [4] - Chinese surgical robot companies face challenges in international markets, including the need for global competitiveness and the establishment of commercial channels [4][5] Group 5: Innovation and Collaboration - The current trend in China is a "one machine, multiple products" model, while overseas markets prefer a "one machine, one product" model, emphasizing the integration of equipment, consumables, and services [5] - Successful internationalization of Chinese surgical robots will require effective resource integration and the establishment of a robust service platform [5][6]

截至2025年8月27日收盘，天智航-U股价报19.30元，较前一交易日下跌5.53%，成交额3.01亿元。 天智航-U所属医疗器械板块，公司专注于骨科手术机器人研发、生产及销售，产品应用于骨科手术导 航定位领域。 公司8月27日晚间披露的半年报显示，2025年上半年实现营业收入1.25亿元，同比增长114.89%，但归属 于上市公司股东的净利润为-5754.82万元，亏损同比有所扩大。 风险提示：股市有风险，投资需谨慎。（本内容由AI生成，仅供参考，不构成投资建议。） 资金流向方面，天智航-U8月27日主力资金净流出1930.63万元，近五日主力资金累计净流出3325.45万 元。 ...

一、董事会会议召开情况 北京天智航医疗科技股份有限公司（以下简称"公司"）第六届董事会第二 十二次会议通知于 2025 年 8 月 19 日以电子邮件方式送达公司全体董事，于 2025 年 8 月 27 日以现场结合通讯方式召开。本次会议应出席董事 9 人，实际出席董 事 9 人，会议由董事长张送根先生主持。本次会议的召集、召开和表决程序符合 《中华人民共和国公司法》《公司章程》的有关规定，会议决议合法有效。 二、董事会会议审议情况 经与会董事表决，形成如下决议： 具体内容详见公司同日刊登在上海证券交易所网站（www.sse.com.cn）的《公 司 2025 年半年度报告》及《公司 2025 年半年度报告摘要》。 表决结果：同意 9 票，反对 0 票，弃权 0 票；通过。 证券代码：688277 证券简称：天智航 公告编号：2025-030 北京天智航医疗科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本议案已经公司董事会审计委员会审议通过。 告>的议案》 报告期，公司严格按照《募集资金管理办法》及《募 ...

证券代码：688277 证券简称：天智航 公告编号：2025-031 北京天智航医疗科技股份有限公司 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 北京天智航医疗科技股份有限公司（以下简称"公司"）第五届监事会第十 次会议通知于 2025 年 8 月 19 日以电子邮件方式送达公司全体监事，于 2025 年 次会议由监事会主席张维军先生主持。本次监事会会议的召开符合《公司法》 《公 司章程》等有关规定，会议决议合法有效。 二、监事会会议审议情况 全体监事以投票方式通过如下决议： 公司 2025 年半年度报告的编制和审议程序符合相关法律法规及《公司章程》 等相关规定；公司 2025 年半年度报告的内容和格式符合相关规定，公允地反映 了公司 2025 年半年度的财务状况和经营成果；2025 年半年度报告编制过程中， 未发现公司参与报告编制和审议的人员有违反保密规定的行为；监事会全体成员 保证公司 2025 年半年度报告披露的信息真实、准确、完整，不存在任何虚假记 载、误导性陈述或重大遗漏，并对其内容的 ...

人民财讯8月27日电，天智航(688277)8月27日晚间披露半年报，2025年上半年，公司实现营业收入1.25 亿元，同比增长114.89%；归属于上市公司股东的净利润-5754.82万元；基本每股收益-0.13元。 ...

Core Viewpoint - Beijing Tinavi Medical Technologies Co., Ltd. reported significant growth in revenue and operational metrics for the first half of 2025, indicating a strong market position in the orthopedic surgical robot industry. Company Overview and Financial Indicators - The company achieved a revenue of approximately 125.31 million yuan, representing a year-on-year increase of 114.89% [2][6] - The net profit attributable to shareholders was approximately -57.55 million yuan, with a decrease in losses of 27.96% compared to the previous year [2][6] - The total assets of the company increased by 5.35% to approximately 1.78 billion yuan [2][6] Business Model and Product Offerings - The company focuses on the development and production of orthopedic surgical robots, with its core product being the "Tianji" series of surgical robots [5][12] - The company employs a hybrid sales model combining direct sales and distribution, providing training and clinical support to medical institutions [7][12] - The company has established a comprehensive R&D system and collaborates with universities and hospitals to enhance its product offerings [14][12] Industry Context - The orthopedic surgical robot industry is experiencing rapid growth, driven by technological advancements and increasing demand for minimally invasive surgeries [8][10] - The company holds a leading market share in China, with its products being used in over 200 medical institutions and completing more than 120,000 surgeries [10][12] - The industry is characterized by high technical barriers, requiring significant R&D investment and collaboration across multiple disciplines [9][10] Innovation and R&D - The company has developed several innovative products, including the Tianji SIRUI orthopedic surgical robot, which enhances surgical precision and efficiency [13][12] - The company has a strong focus on integrating advanced technologies such as AI and multi-modal imaging into its surgical robots [17][18] - The company has filed for 412 patents, establishing a robust technological barrier in the orthopedic surgical robot field [14][12]

第一节 重要提示 规划，投资者应当到上海证券交易所网站（www.sse.com.cn）网站仔细阅读半年度报告全文。 公司已在半年度报告中详细阐述公司在经营过程中可能面临的各种风险及应对措施，敬请查阅半 年度报告第三节"管理层讨论与分析"。 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 无 □适用 √不适用 第二节 公司基本情况 公司股票简况 公司股票简况 股票种类 股票上市交易所 股票简称 股票代码 变更前股票简称 人民币普通股（A股） 上海证券交易所科创板 天智航 688277 不适用 公司存托凭证简况 □适用 √不适用 联系人和联系方式 联系人和联系方式 董事会秘书（信息披露境内代表） 证券事务代表 姓名 黄军辉 孙晓燕 电话 010-82156660-8009 010-82156660-8009 办公地址 北京市海淀区建枫路（南延）中关村 北京市海淀区建枫路（南延）中关村 西三旗金隅科技园8号院2号楼 西三旗金隅科技园8号院2号楼 北京天智航医疗科技股份有限公司2025 年半年度报告摘要 电子信箱 tinavi@tinavi.com tinavi@tinavi.com 单位 ...

北京天智航医疗科技股份有限公司 关于 2023 年限制性股票激励计划首次及预留授予部分 北京天智航医疗科技股份有限公司（以下简称"公司"）监事会依据《中华人 民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以 下简称"《证券法》"）、《上市公司股权激励管理办法》（以下简称"《管理 办法》"）、《上海证券交易所科创板股票上市规则》（以下简称"《上市规则》"） 和《北京天智航医疗科技股份有限公司章程》（以下简称"《公司章程》"）等有 关规定，对本次限制性股票激励计划首次及预留授予部分第二个归属期符合归属 条件的激励对象名单进行审核，发表核查意见如下： 经核查，除 11 名激励对象（首次授予 5 名，预留授予 9 名，首次和预留人 员存在重合）离职外，本激励计划首次及预留授予拟归属的 148 名激励对象（首 次授予 95 名，预留授予 117 名，首次和预留人员存在重合）绩效考核结果合规、 真实，不存在虚假、故意隐瞒等相关情况，符合《公司法》《证券法》等法律、 法规和规范性文件以及《公司章程》规定的任职资格，符合《管理办法》《上市 规则》等法律、法规和规范性文件规定的激励对象条件，符合《公司 ...